Oncology Venture receives 1,000,000 SEK through exercise of warrants of series 2019
Hørsholm, Danmark, March 8th 2017 – Oncology Venture Sweden AB (“Oncology Venture”) announces that Medical Prognosis Institute A/S (”MPI”) has exercised 100,000 of the 302,243 warrants in Oncology Venture that MPI received in return for Oncology Venture’s extended global three year exclusive license to the MPI Drug Response Prediction (DRPTM) technology for drug development and commercialization. Through the exercise of warrants Oncology Venture will receive 1,000,000 SEK.For the warrants of series 2019 the following terms and conditions applies. By exercising warrants of series 2019, the